Synergistic antifibrotic effect of verapamil and interferon-gamma in rats: partially based on enhanced verapamil oral bioavailability.
Xu
Dan
D
Department of Pharmacology, Basic Medical School of Wuhan University, Wuhan 430071, China.
Chen
Man
M
Guo
Yu
Y
Liang
Gai
G
Zhang
Benjian
B
Tan
Jingquan
J
Magdalou
Jacques
J
Wang
Hui
H
D000818:Animals; D000998:Antiviral Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019540:Area Under Curve; D001682:Biological Availability; D002121:Calcium Channel Blockers / Q000493:pharmacokinetics / Q000627:therapeutic use*; D051544:Cytochrome P-450 CYP3A / Q000187:drug effects; D004357:Drug Synergism; D007371:Interferon-gamma / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008106:Liver Cirrhosis, Experimental / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D016896:Treatment Outcome; D014700:Verapamil / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000998:Antiviral Agents; D002121:Calcium Channel Blockers; D007371:Interferon-gamma; D014700:Verapamil; D051544:Cytochrome P-450 CYP3A